Patents by Inventor William F. Brubaker

William F. Brubaker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240092731
    Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
    Type: Application
    Filed: July 14, 2023
    Publication date: March 21, 2024
    Inventors: Yiumo CHAN, Emil D. KAKKIS, Alexandra TROTIER-FAURION, William F. BRUBAKER, Arjun NATESAN, Paul LEE, Sharyl FYFFE-MARICICH, David LAPOINTE, Mike E. LIZARZABURU
  • Creatine prodrugs, compositions and methods of use thereof
    Patent number: 11753369
    Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: September 12, 2023
    Assignee: Ultragenyx Pharmaceutical Inc.
    Inventors: Yiumo Chan, Emil D. Kakkis, Alexandra Trotier-Faurion, William F. Brubaker, Arjun Natesan, Paul Lee, Sharyl Fyffe-Maricich, David Lapointe, Mike E. Lizarzaburu
  • Creatine prodrugs, compositions and methods of use thereof
    Patent number: 11407722
    Abstract: The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine prodrugs or pharmaceutical compositions thereof.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: August 9, 2022
    Assignee: FARMINGTON PHARMA DEVELOPMENT
    Inventor: William F. Brubaker
  • CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220227703
    Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
    Type: Application
    Filed: March 28, 2022
    Publication date: July 21, 2022
    Inventors: Yiumo CHAN, Emil D. KAKKIS, Alexandra TROTIER-FAURION, William F. BRUBAKER, Arjun NATESAN, Paul LEE, Sharyl FYFFE-MARICICH, David LAPOINTE, Mike E. LIZARZABURU
  • Creatine prodrugs, compositions and methods of use thereof
    Patent number: 11332438
    Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: May 17, 2022
    Assignee: Ultragenyx Pharmaceutical Inc.
    Inventors: Yiumo Chan, Emil D. Kakkis, Alexandra Trotier-Faurion, William F. Brubaker, Arjun Natesan, Paul Lee, Sharyl Fyffe-Maricich, David Lapointe, Mike E. Lizarzaburu
  • Creatine phosphate analog prodrugs, compositions and methods of use thereof
    Patent number: 11021501
    Abstract: The invention describes membrane permeable creatine phosphate analog prodrugs, pharmaceutical compositions comprising membrane permeable creatine phosphate analog prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine phosphate analog prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine phosphate analog prodrugs or pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 1, 2021
    Assignee: Farmington Pharma Development
    Inventor: William F. Brubaker
  • CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210002211
    Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
    Type: Application
    Filed: December 3, 2018
    Publication date: January 7, 2021
    Inventors: Yiumo CHAN, Emil D. KAKKIS, Alexandra TROTIER-FAURION, William F. BRUBAKER, Arjun NATESAN, Paul LEE, Sharyl FYFFE-MARICICH, David LAPOINTE, Mike E. LIZARZABURU
  • CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20190337909
    Abstract: The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine prodrugs or pharmaceutical compositions thereof.
    Type: Application
    Filed: May 22, 2019
    Publication date: November 7, 2019
    Inventor: William F. BRUBAKER
  • Creatine prodrugs, compositions and methods of use thereof
    Patent number: 10344007
    Abstract: The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine prodrugs or pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 9, 2019
    Assignee: FARMINGTON PHARMA DEVELOPMENT
    Inventor: William F. Brubaker
  • CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20170342039
    Abstract: The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine prodrugs or pharmaceutical compositions thereof.
    Type: Application
    Filed: April 7, 2017
    Publication date: November 30, 2017
    Inventor: William F. Brubaker
  • Creatine prodrugs, compositions and methods of use thereof
    Patent number: 9617230
    Abstract: The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine prodrugs or pharmaceutical compositions thereof.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: April 11, 2017
    Assignee: FARMINGTON PHARMA DEVELOPMENT
    Inventor: William F. Brubaker
  • CREATINE PHOSPHATE ANALOG PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160289253
    Abstract: The invention describes membrane permeable creatine phosphate analog prodrugs, pharmaceutical compositions comprising membrane permeable creatine phosphate analog prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine phosphate analog prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine phosphate analog prodrugs or pharmaceutical compositions thereof.
    Type: Application
    Filed: March 30, 2016
    Publication date: October 6, 2016
    Inventor: William F. Brubaker
  • CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160176829
    Abstract: The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine prodrugs or pharmaceutical compositions thereof.
    Type: Application
    Filed: December 21, 2015
    Publication date: June 23, 2016
    Applicant: Farmington Pharma Development
    Inventor: William F. Brubaker
  • Phosphodiesterase 4 inhibitors
    Patent number: 7205320
    Abstract: PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R1, R2, R3 and R4 are as defined herein.
    Type: Grant
    Filed: January 12, 2004
    Date of Patent: April 17, 2007
    Assignee: Memory Pharmaceuticals Corp.
    Inventors: Richard A. Schumacher, William F. Brubaker, Michael De Vivo, Hans-Jürgen Ernst Hess, Allen Hopper, Ashok Tehim, Ruiping Liu, Axel Unterbeck
  • Phosphodiesterase 4 inhibitors
    Publication number: 20040230072
    Abstract: PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs.
    Type: Application
    Filed: January 12, 2004
    Publication date: November 18, 2004
    Inventors: Richard A. Schumacher, William F. Brubaker, Michael De Vivo, Hans-Jurgen Ernst Hess, Allen Hopper, Ashok Tehim, Ruiping Liu, Axel Unterbeck
  • Phosphodiesterase 4 inhibitors
    Patent number: 6699890
    Abstract: PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R1, R2 , R3 and R4 are as defined herein.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: March 2, 2004
    Assignee: Memory Pharmaceuticals Corp.
    Inventors: Richard A. Schumacher, William F. Brubaker, Michael De Vivo, Hans-Jürgen Ernst Hess, Allen Hopper, Ashok Tehim, Ruiping Liu, Axel Unterbeck
  • Phosphodiesterase 4 inhibitors
    Publication number: 20030149052
    Abstract: PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs.
    Type: Application
    Filed: February 11, 2003
    Publication date: August 7, 2003
    Applicant: MEMORY PHARMACEUTICALS CORP.
    Inventors: Richard A. Schumacher, William F. Brubaker, Michael De Vivo, Hans-Jurgen Ernst Hess, Allen Hopper, Ashok Tehim, Ruiping Liu, Axel Unterbeck
  • Phosphodiesterase 4 inhibitors
    Publication number: 20020151566
    Abstract: PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs.
    Type: Application
    Filed: January 22, 2002
    Publication date: October 17, 2002
    Applicant: MEMORY PHARMACEUTICALS CORP.
    Inventors: Richard A. Schumacher, William F. Brubaker, Michael De Vivo, Hans-Jurgen Ernst Hess, Allen Hopper, Ashok Tehim, Ruiping Liu, Axel Unterbeck